April 7, 2015 | 1 to 2 p.m. Eastern | Webinar
Since the Patient-Focused Drug Development (PFDD) initiative was launched in 2012, the Food andDrug Administration (FDA) has held or scheduled 14 disease-specific meetings to better understand patients experience with symptoms, impacts on daily living, and available therapies. With more meetings on the docket for 2015, and growing interest among patient groups in applyingthe PFDD model to developing their own data,FasterCuresexamines the experience of organizations engaged in this process.
Tune in to hear insights from patient groups about how they prepared for their PFDD meetings, whatlessons they learned, and how their activities have since been impacted. And find out how groups that do not have a scheduled meeting with FDA are adapting the PFDD model to develop their own information about patient preference and seeking to have it integrated into FDA decision-making.
Kimberly Beer, Director, Public Policy, Susan G. Komen for the Cure
Andrea Ferris, President and Chairman, LUNGevity
Jennifer Sheridan Palute, Director of Policy, Parkinsons Action Network
Moderator:Kim McCleary, Director, Strategic Initiatives,FasterCures